New-Onset Refractory Status Epilepticus (NORSE): literature review and clinical case description
S. G. Burd,
M. B. Mironov,
E. R. Moizykevich,
Yu. V. Rubleva,
M. A. Bogomazova,
А. V. Yurchenko,
T. M. Krasilshchikova,
A. Yu. Suvorov,
A. V. Lebedeva,
R. T. Tairova Abstract
Here we provide a literature-based definition as well as etiological factors, clinical picture, prognosis, diagnostic algorithm, and treatment for the New-Onset Refractory Status Epilepticus (NORSE syndrome). In addition, we also present our personal experience by describing a female patient with refractory focal epilepsy associated with the cryptogenic new-onset refractory status epilepticus.
About the Authors
S. G. Burd
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Sergey G. Burd- MD, Dr Sci Med, Professor at the Department of Neurology, Neurosurgery and Medical Genetics, Faculty of Pediatrics, Pirogov RNRMU, Ministry of Health of the Russian Federation; Head of the Department of Paroxysmal Diseases, Federal Center for Brain and Neurotechnologies FMBA.
1-10 Ostrovityanova Str., Moscow 117997; 1 Ostrovityanova Str., Moscow 117997
M. B. Mironov
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Mikhail B. Mironov - MD, PhD, Leading Researcher, Department of Epilepsy and Paroxysmal Conditions, Scopus ID: 632779; RSCI SPIN-code: 1144-7120.
1-10 Ostrovityanova Str., Moscow 117997
E. R. Moizykevich
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Elena R. Moizykevich - Junior Researcher, Department of Paroxysmal Diseases, Department of Epilepsy and Paroxysmal Conditions.
1-10 Ostrovityanova Str., Moscow 117997
Yu. V. Rubleva
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Yulia V. Rubleva - MD, PhD, Senior Researcher for Epilepsy and Paroxysmal Conditions, Federal Center for Brain and Neurotechnologies FMBA; Head of the Department of Neurology No. 1, Federal Center for Brain and Neurotechnologies of the FMBA.
1-10 Ostrovityanova Str., Moscow 117997M. A. Bogomazova
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Maria A. Bogomazova - neurologist of the Department of Neurology No. 1.
1-10 Ostrovityanova Str., Moscow 117997
А. V. Yurchenko
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Anna V. Yurchenko - neurologist of the Department of Neurology No. 1.
1-10 Ostrovityanova Str., Moscow 117997
T. M. Krasilshchikova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatyana M. Krasilshchikova - MD, Assistant, Chair of Neurology, Neurosurgery and Medical Genetics, Faculty of Pediatrics.
1 Ostrovityanova Str., Moscow 117997
A. Yu. Suvorov
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Andrey Yu. Suvorov - MD, PhD, Scientific Secretary, Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency; Associate Professor of the Department of Medical Rehabilitation, Pirogov RNRMU.
1-10 Ostrovityanova Str., Moscow 117997; 1 Ostrovityanova Str., Moscow 117997
A. V. Lebedeva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Anna V. Lebedeva - MD, Dr Sci Med, Professor at the Department of Neurology, Neurosurgery and Medical Genetics, Faculty of Pediatrics.
1 Ostrovityanova Str., Moscow 117997
R. T. Tairova
Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Raisa T. Tairova - MD, PhD, Deputy Director for Medical Work, Chief Physician of the Federal State Budgetary Institution.
1-10 Ostrovityanova Str., Moscow 117997
References
1. Hirsch L.J., Gaspard N., van Baalen A., Nabbout R., Demeret S., Loddenkemper T., Navarro V., Specchio N., Lagae L., Rossetti A.O., Hocker S., Gofton T.E., Abend N.S., Gilmore E.J., Hahn C., Khosravani H, Rosenow F., Trinka E. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018 Apr; 59 (4): 739-744. https://doi.org/10.1111/epi.14016.
2. Costello D.J., Kilbride R.D., Cole A.J. Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults-Infectious or not? J Neurol Sci. 2009 Feb 15; 277 (1-2): 26-31.
3. Dogan Onugoren M., Deuretzbacher D., Haensch C.A., Hagedorn H.J., Halve S., Isenmann S., et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2015 Sep; 86 (9): 965-72.
4. Gaspard N., Foreman B.P, Alvarez V., Cabrera Kang C., Probasco J.C., Jongeling A.C., et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology. 2015 Nov 3; 85 (18): 1604-13.
5. Gugger J.J., Husari K., Probasco J.C., Cervenka M.C. New onset refractory status epilepticus (NORSE). Seizure. 2020; 74 (1): 41-48. https://doi.org/10.1016/j.seizure.2019.12.002.
6. Spatola M., Novy J., Pasquier Du R., Dalmau J., Rossetti A.O. Status epilepticus of inflammatory etiology: a cohort study. Neurology. 2015 Aug 4; 85 (5): 464-70.
7. Karlov V.A. Epilepsy in children and adult women and men. A Guide for Physicians 2nd Edition. Moscow. 2019; 896 s. (in Russ.).
8. Norse Institute [Electronic resource] URL: http://www.norseinstitute.org/. Accessed: 25.05.2020.
9. Gaspard N., Hirsch L.J., Sculier C., et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018 Apr; 59 (4): 745-752.
10. Gall C.R.E., Jumma O., Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure. 2013 Apr; 22 (3): 217-20.
11. Khawaja A.M., DeWolfe J.L., Miller D.W., Szaflarski J.P. New-onset refractory status epilepticus (NORSE) - The potential role for immunotherapy. Epilepsy Behav. 2015 Jun; 47: 17-23.
12. Li J., Saldivar C., Maganti R.K. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure. 2012 Oct 12; 22 (1): 70-3.
Review
For citations:
Burd S.G., Mironov M.B., Moizykevich E.R., Rubleva Yu.V., Bogomazova M.A., Yurchenko А.V., Krasilshchikova T.M., Suvorov A.Yu., Lebedeva A.V., Tairova R.T. New-Onset Refractory Status Epilepticus (NORSE): literature review and clinical case description. Epilepsy and paroxysmal conditions. 2020;12(3):169-176. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2020.034
Views: 955
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
